TerminatedPhase 4ACTRN12612000034831

CHiRRP: Combating Haemophilus influenzae Related Respiratory Pathology

A multi-centre, double-blind, randomised controlled trial to evaluate the efficacy of 10 valent-pneumococcal-Protein D conjugate vaccine compared to quadrivalent (ACYW135) meningococcal conjugate vaccine in reducing respiratory exacerbations in children aged greater than or equal to 18 months with suppurative lung disease.


Sponsor

University of Queensland

Enrollment

206 participants

Start Date

Feb 1, 2013

Study Type

Interventional

Conditions

Summary

Chronic suppurative lung diseases in children are major causes of morbidity and mortality worldwide, particularly in disadvantaged populations. Repeated infections in childhood contribute to poor lung health in adulthood. The most common organism associated with infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi (10v-PHiD) can reduce repeated respiratory infections in children. We will be comparing the number of respiratory exacerbations in the 12 months following vaccinated between children with chronic lung disease vaccinated with 10vPHiD and children who received a meningococcal vaccine (control vaccine).


Eligibility

Sex: Both males and femalesMin Age: 18 MonthssMax Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether a pneumococcal-Haemophilus vaccine (PHiD-CV) can reduce respiratory infections in children aged 18 months to 18 years with chronic suppurative lung disease or bronchiectasis who have had at least 2 respiratory flare-ups in the past 18 months. Children must have received a meningococcal C vaccine at least 6 months prior. Those with immune deficiency, on immunosuppressive therapy, or who have previously received the study vaccine are excluded.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

10valent pneumococcal - Protein D conjugate vaccine (10vPHiD), 0.5ml intramuscular injection, 2 doses, 2 months apart

10valent pneumococcal - Protein D conjugate vaccine (10vPHiD), 0.5ml intramuscular injection, 2 doses, 2 months apart


Locations(1)

The Royal Childrens Hospital - Parkville

NSW,QLD,WA,VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000034831